[Pharmacokinetics of intramuscular mezlocillin in patients with normal and impaired renal function (author's transl)]. 1982

J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix

Pharmacokinetic values of mezlocillin were determined after a single intramuscular injection of 1 g to 10 subject with normal renal function, 10 patients with stable renal insufficiency and 5 patients with chronic renal failure under long-term haemodialysis. The values obtained in normal subjects were : biological half-life Tb 1/2 0.9 hour; elimination constant Ke 0.790 (h-1); total clearance Ct 449 ml/min/1.73 m2; renal clearance Cr 263 ml/min/1.73 m2. Twelve hours after the injection 72.2 % of the dose administered were recovered in the urine. Theoretical values after repeated injection were calculated from the values obtained in subjects with normal renal function. The loading doses providing steady state serum concentrations were determined for various dosage intervals (2, 3, 4, 6 and 8 hours). In patients with renal insufficiency or treated with haemodialysis, serum levels decreased more slowly. The theoretical Tb 1/2 for zero creatinine clearance was 4.7 hours. Sixty-two percent of the amount of mezlocillin present in the central compartment at the onset of haemodialysis were removed after a 6-hour dialysis session. In all 25 subjects investigated, a significant correlation was found between Ke and Ccr (Ke = 0.1973 + 0.0046 Ccr). This correlation was used to calculate the loading and maintenance doses (and sometimes also the intervals between injections) adjusted to renal function values. Dosage guidelines in relation to the renal function were established from these data.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008802 Mezlocillin Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections. Bay-f 1353,Baypen,Melocin,Meslocillin,Mezlin,Mezlocillin Sodium,Mezlocilline,Bay f 1353,Bayf 1353,Sodium, Mezlocillin
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
February 1982, La Nouvelle presse medicale,
J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
August 1978, Deutsche medizinische Wochenschrift (1946),
J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
June 1978, Deutsche medizinische Wochenschrift (1946),
J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
November 1979, Antimicrobial agents and chemotherapy,
J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
January 1982, The Journal of antimicrobial chemotherapy,
J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
January 1982, The Journal of antimicrobial chemotherapy,
J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
January 1979, Arzneimittel-Forschung,
J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
May 1987, Antimicrobial agents and chemotherapy,
J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
September 1977, The Journal of antimicrobial chemotherapy,
J M Brogard, and F Comte, and J Kopferschmitt, and M Dorner, and Lavillaureix
January 1981, Therapie,
Copied contents to your clipboard!